YouTube video by angelmayan

Hemab Therapeutics (Nasdaq: COAG) reported new clinical and preclinical data for sutacimig in Glanzmann thrombasthenia (GT) and Factor VII deficiency (FVIID) at the ISTH 2026 Congress. Phase 2 long-term extension (LTE) data in GT, covering 34 patients with a median 6.9 months and up to 15.9 months of exposure, showed sustained prophylactic bleed reduction and a manageable safety and tolerability profile. FDA has endorsed proceeding to a Phase 3 trial in 2H 2026 with a 0.2 mg/kg weekly regimen.According to Hemab, 92% of participants who bled during run-in had reduced treated bleed rates on sutacimig, high‑intensity treated bleeds fell by 62%, and the low-dose weekly cohort saw about an 84% reduction in mean annualized treated bleeding rate. Three surgical or procedural cases achieved successful hemostasis. Adverse events were mostly mild or moderate, with three Grade 2 thromboembolic events in higher‑exposure or high‑risk cohorts, all managed with routine anticoagulation. Preclinical FVIID data showed restoration of thrombin generation and binding to most tested variants. Natural history studies (GT360, ATHN Transcends) documented lifelong weekly bleeding, high depressive symptom rates, and low prophylaxis use, reinforcing unmet need.